Akebia Therapeutics (AKBA) Operating Margin: 2016-2025
Historic Operating Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to 7.57%.
- Akebia Therapeutics' Operating Margin rose 4098.00% to 7.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.88%, marking a year-over-year decrease of 22809.00%. This contributed to the annual value of -31.51% for FY2024, which is 43105.00% up from last year.
- According to the latest figures from Q3 2025, Akebia Therapeutics' Operating Margin is 7.57%, which was down 66.43% from 22.55% recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Operating Margin registered a high of 26.97% during Q2 2022, and its lowest value of -149.95% during Q2 2021.
- Over the past 3 years, Akebia Therapeutics' median Operating Margin value was -19.99% (recorded in 2024), while the average stood at -17.12%.
- Data for Akebia Therapeutics' Operating Margin shows a peak YoY increase of 27,473bps (in 2021) and a maximum YoY decrease of 5,733bps (in 2021) over the last 5 years.
- Quarterly analysis of 5 years shows Akebia Therapeutics' Operating Margin stood at -113.28% in 2021, then surged by 10,456bps to -8.73% in 2022, then surged by 766bps to -1.07% in 2023, then tumbled by 2,970bps to -30.77% in 2024, then soared by 4,098bps to 7.57% in 2025.
- Its Operating Margin was 7.57% in Q3 2025, compared to 22.55% in Q2 2025 and 23.57% in Q1 2025.